ANI Pharmaceuticals and Sofgen announced the launch of their Nimodipine Capsules.

Nimodipine is a calcium channel blocker indicated for the improvement of neurological outcome. It does so by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms, regardless of their post-ictus neurological condition (eg, Hunt and Hess Grades I-V).

RELATED: Hematological Disorders Resource Center 

Nimodipine Capsules are available in 30mg strengths.

For more information call (800) 434-1121 or visit